The management of keratoconjuctivitis sicca.
D000777:Anesthetics / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000188:drug therapy; D001639:Bicarbonates / Q000627:therapeutic use*; D002701:Chloramphenicol / Q000627:therapeutic use; D003545:Cysteine / Q000627:therapeutic use; D003911:Dextrans / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D006566:Herpesviridae Infections; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use; D007065:Idoxuridine / Q000627:therapeutic use; D007637:Keratoconjunctivitis / Q000150:complications* / Q000188:drug therapy*; D007765:Lacrimal Apparatus / Q000601:surgery*; D008180:Lupus Erythematosus, Systemic / Q000150:complications; D008747:Methylcellulose / Q000627:therapeutic use*; D009821:Oils / Q000627:therapeutic use; D010232:Paraffin / Q000627:therapeutic use; D012216:Rheumatic Diseases / Q000150:complications; D012965:Sodium Chloride / Q000627:therapeutic use*; D013203:Staphylococcal Infections / Q000150:complications; D013256:Steroids / Q000627:therapeutic use; D013501:Surface-Active Agents; D013666:Tears; D013974:Thyroxine / Q000627:therapeutic use; D014801:Vitamin A / Q000627:therapeutic use
D000777:Anesthetics; D001639:Bicarbonates; D003911:Dextrans; D009821:Oils; D013256:Steroids; D013501:Surface-Active Agents; D014801:Vitamin A; D012965:Sodium Chloride; D006886:Hydroxychloroquine; D002701:Chloramphenicol; D010232:Paraffin; D008747:Methylcellulose; D006493:Heparin; D003545:Cysteine; D007065:Idoxuridine; D013974:Thyroxine